Solanezumab Completed Phase 2 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00329082Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers
NCT00749216Solanezumab Safety Study in Japanese Patients With Alzheimer's Disease